HUMULIN 70/30 INSULIN HUMAN VIAL 10ML @

Indications

Approved Uses

To improve glycemic control in adult patients with diabetes mellitus.

Off-Label Uses

None for this premixed subcutaneous product; hyperkalemia treatment uses IV regular insulin (not premixed 70/30), and gestational diabetes use is not considered off-label for human insulin generally but should follow local labeling/policy.

Dosage & Administration

Dosing by Condition

Individualize dosing. Commonly dosed subcutaneously twice daily (e.g., before breakfast and before the evening meal) about 30 minutes before meals; total daily insulin requirements vary widely (often ~0.4-1 unit/kg/day in type 1 overall insulin needs, and variable in type 2), with titration to fasting and pre-/post-prandial glucose targets.

Maximum Dose

No absolute maximum dose; dose is individualized and titrated to glycemic targets.

Children's Dosage

Not indicated for pediatric use.

Dose Adjustment Notes

Dose adjustments are individualized based on SMBG patterns and glycemic targets; adjust with changes in meals, activity, intercurrent illness, or concomitant drugs. Renal or hepatic impairment increases hypoglycemia risk and often necessitates closer monitoring and possible dose reduction.

How to Take

For subcutaneous injection only. Resuspend by gently rolling/inverting the vial until uniformly cloudy before use. Inject subcutaneously into abdomen, thigh, upper arm, or buttock; rotate injection sites. Administer as directed with meals; use a new sterile syringe/needle each time.

How to Prepare

Before each dose, gently roll and invert the vial several times until the suspension is uniformly cloudy/milky; do not shake vigorously. Inspect for clumps/particles or frosting-do not use if present. Use an insulin syringe calibrated for U-100 to withdraw the prescribed dose.

Side Effects

Common Side Effects

Hypoglycemia; injection-site reactions; lipodystrophy (lipoatrophy/lipohypertrophy); weight gain; edema.

Safety & Warnings

Contraindications

Contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin human or any excipient; not for intravenous administration.

Warnings & Precautions

Major precautions: hypoglycemia risk (most common/serious) and need for close glucose monitoring; any insulin change only under medical supervision; rotate injection sites to prevent lipodystrophy; risk of hypokalemia; monitor for edema/heart failure with TZDs; adjust dose during illness/stress/diet/activity changes; for subcutaneous use only (not IV/IM) and inspect/mix suspension to uniform cloudiness before use.

Drug Interactions

Interaction Severity

MAJOR: Thiazolidinediones (pioglitazone/rosiglitazone) with insulin-risk of fluid retention and heart failure. MODERATE: Agents that increase hypoglycemia risk or mask symptoms (e.g., beta-blockers, ACE inhibitors, salicylates, alcohol) and agents that raise glucose/antagonize insulin (e.g., corticosteroids, thiazide diuretics, sympathomimetics); fluoroquinolones may cause dysglycemia.

Food Interaction

Give approximately 30 minutes before a meal; consistent meal timing/carbohydrate intake is important to reduce hypo-/hyperglycemia risk.

Special Populations

Pregnancy

Consult Doctor

Breastfeeding

Safe

Children

Not indicated for pediatric use.

Elderly

Start at lower doses; titrate slowly with frequent blood glucose monitoring. Elderly patients have increased hypoglycemia risk and may have impaired hypoglycemia awareness. Individualize glycemic targets to avoid hypoglycemia.

Kidney Impairment

No fixed adjustment; renal impairment increases hypoglycemia risk-monitor glucose more frequently and titrate to effect (dose reduction often required as kidney function declines).

Liver Impairment

No fixed adjustment; hepatic impairment increases hypoglycemia risk-use more frequent glucose monitoring and titrate to effect (dose reduction may be needed).

Storage & Patient Advice

Storage Conditions

Store in a refrigerator (2°C - 8°C)

Preparation Instructions

Before each dose, gently roll and invert the vial several times until the suspension is uniformly cloudy/milky; do not shake vigorously. Inspect for clumps/particles or frosting-do not use if present. Use an insulin syringe calibrated for U-100 to withdraw the prescribed dose.

Missed Dose

If a dose is missed, check blood glucose and contact the prescriber/diabetes care team for individualized instructions; do not double the next dose. If close to the next scheduled dose, generally skip the missed dose and resume the usual schedule with extra monitoring.

Stopping the Medicine

Do not stop or change insulin without medical supervision; abrupt discontinuation can cause severe hyperglycemia and may precipitate DKA in insulin-dependent patients.

Overdose

Overdose primarily causes hypoglycemia (and may cause hypokalemia); treat with oral fast-acting carbohydrate if mild, and for severe episodes give glucagon IM/SC or IV dextrose with urgent medical care and continued monitoring.

Patient Counseling

Gently roll/invert the vial to mix until uniformly cloudy; do not shake. Inject subcutaneously about 30 minutes before a meal and eat on time to reduce hypoglycemia risk. Use U-100 insulin syringes, rotate injection sites, and do not share needles/syringes. Monitor blood glucose and recognize/treat hypoglycemia (carry fast-acting glucose). Store correctly (refrigerate unopened; do not freeze; protect from heat/light) and inspect-do not use if clumped/particles or not uniformly cloudy after mixing; carry medical ID and consult prescriber before dose changes.

Monitoring Requirements

Self-monitoring of blood glucose (fasting and pre-meal; additional post-meal/bedtime as needed during titration), periodic HbA1c (typically every ~3 months until stable), monitor for hypoglycemia, weight and injection sites; monitor serum potassium in at-risk patients and renal function as clinically indicated.

Pharmacology

Mechanism of Action

Humulin 70/30 is a premix of 70% NPH (insulin isophane; intermediate-acting) and 30% regular human insulin (short-acting). It binds insulin receptors to increase peripheral glucose uptake and inhibit hepatic glucose output, providing both prandial and basal glycemic control.

Onset of Action

Approximately 30 minutes (due to the regular insulin component); the NPH component has a later onset around 1-2 hours.

Duration of Effect

Up to about 18-24 hours (variable).

Half-Life

Plasma half-life of circulating human insulin is short (~5-10 minutes), but the clinical duration is governed by absorption: Humulin 70/30 typically has onset ~30 minutes, peak ~2-12 hours, and duration up to ~18-24 hours (variable).

Bioavailability

Not well-defined/variable; no single reliable % bioavailability is established for subcutaneous premixed human insulin (absorption is highly variable by site, depth, temperature, and mixing).

Metabolism

Primarily degraded by proteolysis (insulinase/IDE) in liver, kidney, and muscle; kidney and liver are major contributors to overall clearance.

Excretion

Insulin is cleared primarily by enzymatic degradation with significant renal contribution to clearance; metabolites are eliminated via the kidneys (renal impairment reduces insulin clearance).

Protein Binding

Negligible/none clinically significant.

Product Information

Available Dosage Forms

Suspension for injection, vial (10 mL) for subcutaneous use.

Composition per Dose

Each 1 mL: 100 IU insulin human - comprising 70 IU insulin isophane (NPH) + 30 IU regular human insulin. Each 10 mL vial contains 1000 IU total.

Generic Availability

No

OTC Alternatives

No OTC alternative

Diabetes Type

Both

Insulin Type

Pre-mixed

Legal Disclaimer - Al Mujtama Pharmacy The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment. Al Mujtama Pharmacy assumes no legal or medical liability for: Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist Any discrepancy between the information provided and the product's package insert or SFDA guidelines Any misuse of medication resulting from personal interpretation of the content displayed Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication. By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation. Your health is a trust - always consult your doctor first.